Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3801-3810 Newer>

BusinessWeek June 18, 2007 Arlene Weintraub	Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific.
The Motley Fool June 8, 2007 Brian Lawler	Lilliputian Attack on Lilly? While every investor should have some degree of exposure to pharmaceutical stocks, recent patent decisions in two of the biggest pharmaceutical drugs markets should serve as a warning of the potential litigation dangers when investing in some of the sector's giants.
The Motley Fool June 8, 2007 Brian Lawler	A Conversation With Alexza An interview with Alexza Pharmaceuticals' president and CEO on the company's technology and drug pipeline.
The Motley Fool June 8, 2007 Brian Lawler	QLT Eats Itself The beleaguered specialty pharmaceutical opens up another share buyback plan.
The Motley Fool June 7, 2007 Brian Lawler	Acquisitive Amgen The biotech behemoth acquires Ilypsa and Alantos Pharmaceuticals. The all-cash deals for both companies gives Amgen several mid-stage drug candidates to beef up its drug pipeline.
The Motley Fool June 6, 2007 Brian Orelli	Cure Your Cancer or Your Money Back Janssen-Cilag, a subsidiary of Johnson & Johnson, has recently offered to refund the cost of Velcade to the British National Health Service if the patient fails to respond to its multiple myeloma drug. Drug-company investors need not worry about these kinds of deals.
The Motley Fool June 6, 2007 Brian Lawler	Is Telik Insane? Shares of Telik fall after the FDA puts a halt to trials with its lead drug. Even at this reduced share price, investors should stay far away from this pharma.
InternetNews June 5, 2007 Roy Mark	Former Lawmakers Push E-Health on The Hill Coalition aims to pressure Congress to provide funding for an electronic medical records network.
The Motley Fool June 5, 2007 Billy Fisher	Onyx on Fire It is readily apparent that investors in the biopharma will sink or swim on the future results of Nexavar. The ASCO meeting marks an integral win for the company, but only time will tell whether the drug can push the company into the black.
The Motley Fool June 5, 2007 Brian Lawler	Dendreon Gets Its Funding Dendreon does a financing to secure its near-term future. Investors who fail to pay attention to relative valuations of the different stocks in the development-stage biotech space do so at their own peril.
<Older 3801-3810 Newer> Return to current articles.